Overview
- Aurora’s board and its special committee unanimously recommended shareholders take no action and withdraw any tendered shares in a directors’ circular filed on Sept. 2, 2026, saying the unsolicited bid is not in shareholders’ best interests.
- Curaleaf responded the same day by reaffirming its offer, saying it delivers a 45% headline premium and urging shareholders to accept what it calls immediate value plus upside in a larger, diversified company.
- The companies’ filings show contrasting balance sheets: Aurora reports it is debt‑free with about US$149 million in cash, while Curaleaf carries more than US$1 billion of debt but points to recent positive operating cash flow and a US$500 million senior note sale as support for its leverage.
- Aurora warned the proposed exchange ratio would leave its holders with roughly 7.7% of the combined company economically and about 3.2% of voting power, a change it says would meaningfully weaken shareholder rights.
- No negotiations or revised price have been announced; the next steps depend on how Aurora shareholders respond to the offers and on broader sector drivers such as U.S. federal rescheduling and tax changes that are shaping M&A valuations.